Details
| Original language | English |
|---|---|
| Pages (from-to) | 454-466 |
| Number of pages | 13 |
| Journal | Journal of Dietary Supplements |
| Volume | 17 |
| Issue number | 4 |
| Early online date | 22 Jun 2019 |
| Publication status | Published - 3 Jul 2020 |
Abstract
Magnesium (Mg 2+) is one of the most frequently supplemented micronutrients. Due to possible gastrointestinal side effects, the European Food Safety Authority and the Institute of Medicine set the upper intake level for Mg 2+ from supplements to 250 and 350 mg, respectively. Nevertheless, systematic data concerning the tolerability of Mg 2+ supplements are scarce. The aim of the study was to directly compare the bioavailability and tolerability of two 500 mg Mg 2+ supplements in a crossover study with duplicate determination. The different release properties were either a direct release (one phase) or a delayed release of the second half (two phases). An open-label, controlled trial with a crossover design, duplicate determination, and one-week washout phases was conducted. The participants ingested the test product after overnight fasting. Blood samples were taken at baseline and after 1, 2, 3, 4, 6, and 8 hours, and urine was collected over a period of 24 hours. The participants were on standardized nutrition during all examination days. There were no significant differences between the test products regarding 24-hour renal Mg 2+ excretion and area under the curve of serum Mg 2+ levels for 8 hours. Both test products were well tolerated with a very low frequency of gastrointestinal adverse effects and no significant differences between the test products. The Mg 2+ bioavailability did not differ between the test products. The supplements examined had the same good tolerability. Both test products are therefore suited to enhance Mg 2+ supply without relevant side effects.
Keywords
- bioavailability, general nutrition, magnesium, supplement, tolerability
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Food Science
- Nursing(all)
- Nutrition and Dietetics
- Medicine(all)
- Pharmacology (medical)
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Journal of Dietary Supplements, Vol. 17, No. 4, 03.07.2020, p. 454-466.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Magnesium Bioavailability and Tolerability Do Not Differ between Two Supplements with Different Release Properties
AU - Greupner, Theresa
AU - Schneider, Inga
AU - Gellert, S.
AU - Hahn, Andreas
N1 - Funding information: The authors thank the participants who took part in this study. This study was in part funded by Merz Consumer Care (Frankfurt a. M., Germany). Study realization, data analysis, and reporting were undertaken independently from the sponsor.
PY - 2020/7/3
Y1 - 2020/7/3
N2 - Magnesium (Mg 2+) is one of the most frequently supplemented micronutrients. Due to possible gastrointestinal side effects, the European Food Safety Authority and the Institute of Medicine set the upper intake level for Mg 2+ from supplements to 250 and 350 mg, respectively. Nevertheless, systematic data concerning the tolerability of Mg 2+ supplements are scarce. The aim of the study was to directly compare the bioavailability and tolerability of two 500 mg Mg 2+ supplements in a crossover study with duplicate determination. The different release properties were either a direct release (one phase) or a delayed release of the second half (two phases). An open-label, controlled trial with a crossover design, duplicate determination, and one-week washout phases was conducted. The participants ingested the test product after overnight fasting. Blood samples were taken at baseline and after 1, 2, 3, 4, 6, and 8 hours, and urine was collected over a period of 24 hours. The participants were on standardized nutrition during all examination days. There were no significant differences between the test products regarding 24-hour renal Mg 2+ excretion and area under the curve of serum Mg 2+ levels for 8 hours. Both test products were well tolerated with a very low frequency of gastrointestinal adverse effects and no significant differences between the test products. The Mg 2+ bioavailability did not differ between the test products. The supplements examined had the same good tolerability. Both test products are therefore suited to enhance Mg 2+ supply without relevant side effects.
AB - Magnesium (Mg 2+) is one of the most frequently supplemented micronutrients. Due to possible gastrointestinal side effects, the European Food Safety Authority and the Institute of Medicine set the upper intake level for Mg 2+ from supplements to 250 and 350 mg, respectively. Nevertheless, systematic data concerning the tolerability of Mg 2+ supplements are scarce. The aim of the study was to directly compare the bioavailability and tolerability of two 500 mg Mg 2+ supplements in a crossover study with duplicate determination. The different release properties were either a direct release (one phase) or a delayed release of the second half (two phases). An open-label, controlled trial with a crossover design, duplicate determination, and one-week washout phases was conducted. The participants ingested the test product after overnight fasting. Blood samples were taken at baseline and after 1, 2, 3, 4, 6, and 8 hours, and urine was collected over a period of 24 hours. The participants were on standardized nutrition during all examination days. There were no significant differences between the test products regarding 24-hour renal Mg 2+ excretion and area under the curve of serum Mg 2+ levels for 8 hours. Both test products were well tolerated with a very low frequency of gastrointestinal adverse effects and no significant differences between the test products. The Mg 2+ bioavailability did not differ between the test products. The supplements examined had the same good tolerability. Both test products are therefore suited to enhance Mg 2+ supply without relevant side effects.
KW - bioavailability
KW - general nutrition
KW - magnesium
KW - supplement
KW - tolerability
UR - http://www.scopus.com/inward/record.url?scp=85067896181&partnerID=8YFLogxK
U2 - 10.1080/19390211.2019.1629146
DO - 10.1080/19390211.2019.1629146
M3 - Article
VL - 17
SP - 454
EP - 466
JO - Journal of Dietary Supplements
JF - Journal of Dietary Supplements
SN - 1939-0211
IS - 4
ER -